Susser Petroleum (SUSP): CEO and Chairman of the Board Sam L. Susser Bought 351,220 Shares
CEO and Chairman of the Board of (SUSP) Susser Petroleum Partners Sam L. Susser bought 351,220 shares on 09/25/2012 at an average price of $24. Susser Petroleum Partners LP is primarily engaged in fee-based wholesale distribution of motor fuels to Susser Holdings Corporation and third parties. Susser Petroleum has a market cap of $262.53 million; its shares were traded at around $24 .
SUSP recently reported strong financial and operating results for the second quarter ended July 1, 2012. Same-store merchandise sales increased by 8 percent, compared with growth of 5.8 percent in the prior-year period. Average retail gallons per store also increased 8 percent year-over-year, versus growth of 3.6 percent a year earlier.
Executive Vice President, CFO and Treasurer Mary E. Sullivan bought 25,000 shares of SUSP stock on 09/25/2012 at the average price of $20.5. Mary E. Sullivan owns at least 5,000 shares after this. The price of the stock has increased by 17.07% since. Other insiders have also increased their positions in the company.
Rovi Corporation (ROVI): President and CEO Tom Carson Bought 15,000 Shares
President and CEO of Rovi Corporation (ROVI) Tom Carson bought 15,000 shares on 09/25/2012 at an average price of $14.51. Rovi Corporation, formerly Macrovision Solutions Corporation, provides a set of solutions that enable businesses to protect, enable and distribute their digital goods to consumers and allows consumers the ability to discover and manage digital media across multiple channels. Rovi Corporation has a market cap of $1.58 billion; its shares were traded at around $14.51 with a P/E ratio of 11.61 and P/S ratio of 2.29. Rovi Corporation had an annual average earnings growth of 6.1% over the past 10 years. GuruFocus rated Rovi Corporation the business predictability rank of 2.5-star.
Jean-Marie Eveillard owns 184 shares as of 06/30/2012, which accounts for less than 0.01% of the $25.72 billion portfolio of First Eagle Investment Management LLC. PRIMECAP Management sold out his holdings in the quarter that ended on 06/30/2012.
CFO Peter Halt sold 2,691 shares of ROVI stock on 09/04/2012 at the average price of 14.16. Peter Halt owns at least 58,757 shares after this. The price of the stock has increased by 2.47% since.
Zale Corporation (ZLC): CEO Theo Killion Bought 4,000 Shares
CEO of Zale Corporation (ZLC) Theo Killion bought 4,000 shares on 09/24/2012 at an average price of $6.9. Zale Corporation is a specialty retailer of fine jewelry. Zale Corporation has a market cap of $222.32 million; its shares were traded at around $6.9 with and P/S ratio of 0.12.
Zale recently reported its fiscal fourth quarter 2012 financial results. Revenues were $407 million, an increase of $30 million, or 7.9 percent, compared to $377 million in the fourth quarter of fiscal 2011.
10% Owner Capital Management LLC Breeden sold 256,343 shares of ZLC stock on 05/15/2012 at the average price of 2.27. Capital Management LLC Breeden owns at least 5,679,071 shares after this.
Midway Gold Corp. (MDW): President and CEO Kenneth Arnold Brunk Bought 12,000 Shares
President and CEO of Midway Gold Corp. (MDW) Kenneth Arnold Brunk bought 12,000 shares on 09/25/2012 at an average price of $1.64. Midway Gold Corp. is a precious metals company with a vision to explore, design, build, and operate gold mines. Midway Gold Corp. has a market cap of $209.71 million; its shares were traded at around $1.64 .
Chris Davis owns 25,000 shares as of 06/30/2012, which accounts for less than 0.01% of the $43.07 billion portfolio of Davis Selected Advisers.
Progenics Pharmaceuticals Inc. (PGNX): CEO Mark Robert Baker Bought 1,036 Shares
CEO of Progenics Pharmaceuticals Inc. (PGNX) Mark Robert Baker bought 1,036 shares on 09/26/2012 at an average price of $2.88. Progenics Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development & commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics Pharmaceuticals Inc. has a market cap of $97.58 million; its shares were traded at around $2.88 with and P/S ratio of 1.15.
PGNX recently reported its second quarter 2012 financial results. Net loss for the quarter was $10.7 million or $0.32 basic and diluted per share, compared to net income of $55.5 million or $1.64 per share in 2011.
Senior Vice President Medical Affairs Robert J. Israel sold 1,000 shares of PGNX stock on 07/02/2012 at the average price of $9.79. Robert J. Israel owns at least 35,050 shares after this. The price of the stock has decreased by 70.58% since. Other insiders have also increased their positions in the company.
For the complete list of stocks that bought by their company CEOs, go to: [url=http://www.gurufocus.com/InsiderBuy.php?position=ceo]CEO Buys[/url].
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys:: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.